Delee GTM brain

category

market profile

• text: Rare circulating tumor cells are difficult to isolate and characterize; research platforms differ in capture method, cell recovery and downstream assay compatibility.
• text: CytoCatch combines automated isolation with imaging and supports downstream molecular analysis, according to Delee.
• text: A 2026 third-party review reported no identified FDA clearance or approval under Delee or CytoCatch as of its September check; confirm current status and intended use directly.

personas

• title: Cancer research principal investigator
  pains:

  • Rare tumor cells are hard to recover consistently from blood
  • Restricted staining panels can limit the questions a study can answer
• title: Translational oncology laboratory director
  pains:

  • Manual isolation may cause variability and cell loss
  • The lab needs isolated cells compatible with imaging and molecular assays
• title: Oncology biopharma biomarker lead
  pains:

  • Needs interpretable rare-cell data across research samples
  • Must validate platform recovery and workflow fit before investing in an instrument

icp

• text: Academic cancer centers and translational research laboratories running CTC or liquid-biopsy programs; no employee-size threshold is public.
• text: Pharma and biotechnology research teams seeking cell isolation, customizable immunostaining and downstream molecular characterization are plausible buyers.

message pillars

• text: Reduce manual variability through automated isolation.
• text: Let researchers design their own assay panels.
• text: Enable molecular study beyond counting cells.

objections

• objection: Is this authorized for clinical treatment decisions?
  response: Verify regulatory status and validation for the precise jurisdiction and intended use; current research materials do not establish clinical authorization.
• objection: Will it recover the cells relevant to our study?
  response: Compare recovery, viability and reproducibility on representative samples against the current laboratory method.
• objection: Will our antibody panels and sequencing workflow work?
  response: Test the intended staining and downstream protocols in a laboratory pilot.

competitors

• name: Menarini Silicon Biosystems
  why: CellSearch is an established CTC enrichment and enumeration system.
• name: ANGLE plc
  why: Parsortix captures circulating tumor cells for downstream analysis.
• name: RareCyte
  why: Provides rare-cell analysis technologies and appears among competitors in Delee's filing.
• name: Epic Sciences
  why: Offers CTC analysis for research and clinical development applications.

influencers

• name: Liza Velarde
  url: https://kingscrowd.com/founder-profile-delee-liza-velarde/
  why: Delee cofounder discussed the research market and company vision in an interview.

keywords

• circulating tumor cell isolation
• CTC research platform
• liquid biopsy research instrument
• automated rare cell imaging
• CTC molecular analysis
• cancer biomarker research

voice

• scientific
• optimistic
• research focused

signals

• text: An oncology lab starts a CTC study requiring repeatable isolation and molecular characterization.
• text: A research group is evaluating adjustable fluorescent staining panels or reducing manual cell-processing steps.

pricing

motion

channels

• Website
• Scientific publications
• Research partnerships

confidence

Founders

• name: Liza Velarde
  title: Founder
  role: Founder
  bio: Co-Founder and acting CEO at Delee Corp. Velarde has been responsible for the development and execution of the company's strategic plans. Velarde's outstanding work has been highly regarded by international institutions such as Cartier Women's Initiative Awards and WeXchange (from the Inter-American Development Bank). She also lead and supervised the development of the Zen FluidicsTM scientific line, a group of products that enables researchers to develop their own microfluidic applications.
• name: Alejandro Abarca-Blanco
  title: Founder
  role: Founder
• name: Juan Felipe Yee De León
  title: Founder
  role: Founder